undefined undefined
NaN.000
NaN.00%
TCR2 Therapeutics (NASDAQ:TCRR) reported its Q1 earnings results on Thursday, M...
2023-05-11 20:11
TCR2 Therapeutics (NASDAQ:TCRR) reported quarterly losses of $(1.03) per share. This is a 35.53 percent decrease over losses of $(0.76) per share from the same period last year.
2023-05-11 18:46
DUBLIN, May 8, 2023 /PRNewswire/ -- The "Pancreatic Cancer - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering. This "Pancreatic Cancer- Competitive la...
2023-05-08 23:00
The Dow Jones jumped more than 500 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
2023-05-08 19:41
TCR2 Therapeutics (NASDAQ:TCRR – Get Rating) and Fate Therapeutics (NASDAQ:FATE...
2023-04-20 16:59
TCR2 Therapeutics Inc. (NASDAQ:TCRR – Get Rating) has received a consensus reco...
2023-04-01 16:22
12月31日,Tcr2 Therapeutics Inc(TCRR.US)公布财报,公告显示公司2022财年净利润为-1.52亿美元,同比减少52.29%;其中...
2023-03-28 19:16
TCR2 Therapeutics (NASDAQ: TCRR) recently received a number of ratings updates ...
2023-03-27 14:43
TCR2 Therapeutics (NASDAQ: TCRR) recently received a number of ratings updates ...
2023-03-27 14:43
TCR2 Therapeutics (NASDAQ:TCRR – Get Rating) was downgraded by equities researc...
2023-03-26 16:02